Poinciana Advisors Group LLC Invests $279,000 in Natera, Inc. (NASDAQ:NTRA)

Poinciana Advisors Group LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,763 shares of the medical research company’s stock, valued at approximately $279,000.

A number of other large investors have also modified their holdings of the business. Wellington Management Group LLP grew its stake in shares of Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after acquiring an additional 1,883,481 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Natera by 3.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock worth $315,194,000 after acquiring an additional 85,236 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Natera by 7.4% during the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock worth $265,747,000 after acquiring an additional 143,825 shares during the last quarter. Maverick Capital Ltd. boosted its position in Natera by 25.2% in the third quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock valued at $170,119,000 after buying an additional 269,706 shares during the last quarter. Finally, Castle Hook Partners LP boosted its position in Natera by 27.4% in the third quarter. Castle Hook Partners LP now owns 1,140,090 shares of the medical research company’s stock valued at $144,734,000 after buying an additional 245,505 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

NASDAQ NTRA opened at $148.22 on Friday. The stock has a market cap of $20.04 billion, a PE ratio of -84.22 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The stock has a fifty day simple moving average of $164.09 and a 200-day simple moving average of $148.21.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on NTRA. Piper Sandler upped their target price on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. Royal Bank of Canada began coverage on Natera in a research report on Thursday. They issued an “outperform” rating and a $251.00 target price on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. Guggenheim upped their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. Finally, JPMorgan Chase & Co. upped their target price on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $178.12.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total transaction of $859,740.00. Following the completion of the transaction, the insider now directly owns 143,768 shares in the company, valued at $20,600,516.72. This trade represents a 4.01 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider John Fesko sold 663 shares of the firm’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the transaction, the insider now owns 156,044 shares of the company’s stock, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 298,946 shares of company stock worth $47,803,462 in the last three months. 7.60% of the stock is owned by company insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.